Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Jones

Showing results (361-370 of 3,661) with videos related to

Pageof 367
Sort By:
Journal of Receptor Research|January 1, 1990
The role of insulin receptor sulphydryl groups in insulin binding and cellular response in rat adipocytesA G Douen, M N Jones
Diagnostic Microbiology and Infectious Disease|April 1, 2000
Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolatesA C Gales, R N Jones
Diagnostic Microbiology and Infectious Disease|April 15, 2000
Fluoroquinolone-resistant Haemophilus influenzae: frequency of occurrence and analysis of confirmed strains in the SENTRY antimicrobial surveillance program (North and Latin America)D J Biedenbach, R N Jones
Anaesthesia|December 21, 2000
A modification to the codmantrade mark microsensortrade mark skull bolt KitG N Jones, J M Barker
The Journal of Antimicrobial Chemotherapy|November 7, 2000
MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: resistance implications in the treatment of serious infections. MYSTIC Study Group (Americas)M A Pfaller, R N Jones
Experimental Cell Research|November 22, 2001
Cyclin-mediated export of human Orc1H Laman, G Peters, N Jones
Diagnostic Microbiology and Infectious Disease|June 23, 2000
Antimicrobial activity of advanced-spectrum fluoroquinolones tested against more than 2000 contemporary bacterial isolates of species causing community-acquired respiratory tract infections in the United States (1999)L M Deshpande, R N Jones
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 13, 2000
In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance programR N Jones, M A Pfaller
Antimicrobial Agents and Chemotherapy|October 1, 1988
Antimicrobial activity, spectrum, and recommendations for disk diffusion susceptibility testing of ceftibuten (7432-S; SCH 39720), a new orally administered cephalosporinR N Jones, A L Barry
Chemical Communications (Cambridge, England)|March 3, 2005
pi-Indenyl tin(II) and lead(II) compoundsJamie N Jones, Alan H Cowley
Pageof 367

Showing results (361-370 of 3,661) with videos related to

Sort By:
Pageof 367
Journal of Receptor Research|January 1, 1990
The role of insulin receptor sulphydryl groups in insulin binding and cellular response in rat adipocytesA G Douen, M N Jones
Diagnostic Microbiology and Infectious Disease|April 1, 2000
Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolatesA C Gales, R N Jones
Diagnostic Microbiology and Infectious Disease|April 15, 2000
Fluoroquinolone-resistant Haemophilus influenzae: frequency of occurrence and analysis of confirmed strains in the SENTRY antimicrobial surveillance program (North and Latin America)D J Biedenbach, R N Jones
Anaesthesia|December 21, 2000
A modification to the codmantrade mark microsensortrade mark skull bolt KitG N Jones, J M Barker
The Journal of Antimicrobial Chemotherapy|November 7, 2000
MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: resistance implications in the treatment of serious infections. MYSTIC Study Group (Americas)M A Pfaller, R N Jones
Experimental Cell Research|November 22, 2001
Cyclin-mediated export of human Orc1H Laman, G Peters, N Jones
Diagnostic Microbiology and Infectious Disease|June 23, 2000
Antimicrobial activity of advanced-spectrum fluoroquinolones tested against more than 2000 contemporary bacterial isolates of species causing community-acquired respiratory tract infections in the United States (1999)L M Deshpande, R N Jones
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 13, 2000
In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance programR N Jones, M A Pfaller
Antimicrobial Agents and Chemotherapy|October 1, 1988
Antimicrobial activity, spectrum, and recommendations for disk diffusion susceptibility testing of ceftibuten (7432-S; SCH 39720), a new orally administered cephalosporinR N Jones, A L Barry
Chemical Communications (Cambridge, England)|March 3, 2005
pi-Indenyl tin(II) and lead(II) compoundsJamie N Jones, Alan H Cowley
Pageof 367